The Hype And The Data Behind This Breast Cancer Stock’s Massive Surge

The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment. For a look at the hype surrounding the stock and whether it’s a good speculative buy right now, CLICK HERE.